Your browser is no longer supported. Please, upgrade your browser.
Annovis Bio, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.10% Shs Outstand6.90M Perf Week-2.84%
Market Cap155.19M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.09M Perf Month-15.69%
Income-5.50M PEG- EPS next Q- Inst Own19.10% Short Float3.95% Perf Quarter12.07%
Sales- P/S- EPS this Y-498.10% Inst Trans1.12% Short Ratio0.73 Perf Half Y376.52%
Book/sh1.09 P/B20.11 EPS next Y- ROA-55.80% Target Price- Perf Year497.28%
Cash/sh1.14 P/C19.16 EPS next 5Y- ROE-59.30% 52W Range3.36 - 47.99 Perf YTD190.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.32% Beta-
Dividend %- Quick Ratio14.00 Sales past 5Y- Gross Margin- 52W Low552.38% ATR2.11
Employees2 Current Ratio14.00 Sales Q/Q- Oper. Margin- RSI (14)42.30 Volatility8.79% 8.60%
OptionableNo Debt/Eq0.00 EPS Q/Q-740.80% Profit Margin- Rel Volume0.22 Prev Close22.19
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume220.42K Price21.92
Recom2.00 SMA20-5.17% SMA50-18.63% SMA20075.67% Volume49,031 Change-1.22%
May-06-21 06:45AM  
Apr-29-21 07:00AM  
Apr-24-21 03:44AM  
Apr-15-21 07:30AM  
Mar-18-21 11:21AM  
Mar-17-21 06:45AM  
Mar-16-21 09:24AM  
Mar-11-21 07:05AM  
Mar-10-21 07:00AM  
Mar-09-21 07:30AM  
Feb-16-21 06:45AM  
Feb-04-21 06:45AM  
Feb-02-21 06:45AM  
Jan-24-21 01:29AM  
Jan-05-21 06:45AM  
Dec-17-20 06:45AM  
Dec-15-20 06:45AM  
Dec-07-20 04:05PM  
Dec-03-20 09:15AM  
Nov-26-20 07:55PM  
Nov-16-20 09:15AM  
Nov-12-20 06:45AM  
Nov-02-20 06:45AM  
Oct-29-20 06:45AM  
Oct-26-20 06:35AM  
Oct-22-20 06:45AM  
Oct-20-20 06:45AM  
Oct-15-20 06:45AM  
Oct-12-20 04:05PM  
Sep-29-20 06:45AM  
Sep-03-20 06:45AM  
Sep-01-20 06:45AM  
Aug-31-20 05:00PM  
Aug-25-20 08:00AM  
Aug-20-20 06:45AM  
Aug-05-20 09:00AM  
Jul-28-20 07:22AM  
Jul-20-20 06:45AM  
Jul-07-20 06:45AM  
Jun-16-20 06:45AM  
Jun-09-20 06:45AM  
Jun-03-20 09:00AM  
Jun-02-20 06:45AM  
Jun-01-20 06:45AM  
May-27-20 06:45AM  
May-01-20 06:00AM  
Apr-30-20 06:45AM  
Apr-29-20 06:09AM  
Apr-23-20 07:00AM  
Apr-13-20 05:30PM  
Mar-19-20 09:00AM  
Feb-27-20 06:45AM  
Feb-20-20 07:00AM  
Feb-13-20 11:40AM  
Jan-31-20 11:46AM  
Jan-28-20 11:31PM  
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.